AGM/EGMMay 27, 2026, 05:01 AM
Agomab AGM Approves Financials, Reappoints Directors
AI Summary
Agomab Therapeutics NV announced the results of its Annual General Meeting (AGM) held on May 26, 2026. All items on the agenda were approved, including the statutory financial statements for the financial year ended December 31, 2025. Shareholders also approved the discharge of current and former Board members and the statutory auditor, and reappointed Mr. Ohad Hammer for a one-year term and Mr. Tim Knotnerus for a four-year term to the Board of Directors.
Key Highlights
- Annual General Meeting held on May 26, 2026.
- All agenda items were approved by shareholders.
- Statutory financial statements for the financial year ended December 31, 2025, were approved.
- Discharge granted to current and former Board members and the statutory auditor for FY2025 duties.
- Mr. Ohad Hammer reappointed to the Board of Directors for a one-year term.
- Mr. Tim Knotnerus reappointed to the Board of Directors for a four-year term.
Price Impact
More from AGMB